Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)147-157
JournalExpert Review of Anticancer Therapy
Volume16
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Cite this

@article{0775da24c61743c7a6172dddccaf806b,
title = "Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib",
keywords = "resistance mutation. EML-ALK, anaplastic lymphoma kinase, ceritinib, Acquired resistance, tyrosine kinase inhibitors, crizotinib",
author = "Muller, {Ittai B.} and {De Langen}, {Adrianus J.} and Honeywell, {Richard J.} and Elisa Giovannetti and Peters, {Godefridus J.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/14737140.2016.1131612",
language = "English",
volume = "16",
pages = "147--157",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

AU - Muller, Ittai B.

AU - De Langen, Adrianus J.

AU - Honeywell, Richard J.

AU - Giovannetti, Elisa

AU - Peters, Godefridus J.

PY - 2016/2/1

Y1 - 2016/2/1

KW - resistance mutation. EML-ALK

KW - anaplastic lymphoma kinase

KW - ceritinib

KW - Acquired resistance

KW - tyrosine kinase inhibitors

KW - crizotinib

U2 - 10.1586/14737140.2016.1131612

DO - 10.1586/14737140.2016.1131612

M3 - Article

VL - 16

SP - 147

EP - 157

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -